SCHEMBL2000221

SCHEMBL2000221

Cc1ccc2nc(Oc3cc(Cl)cc(NS(=O)(=O)c4ccc(C(F)(F)F)cc4Cl)c3)sc2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 5/20 0.47
CYP3A4 P08684 2/20 0.47
RORC P51449 4/20 0.43
MCL1 Q07820 2/20 0.42
PTGDR2 Q9Y5Y4 1/20 0.39
MAPT P10636 4/20 0.39
LMNA P02545 3/20 0.39
HTT P42858 2/20 0.39
POLB P06746 1/20 0.39
ALDH1A1 P00352 4/20 0.39
GLA P06280 3/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
GAA P10253 3/20 0.39
HPGD P15428 3/20 0.39
MEN1 O00255 2/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
KMT2A Q03164 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
KDM4E B2RXH2 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1997363 0.92 PPARG (0.49) PPARGCYP3A4MCL1PTGDR2MAPT
SCHEMBL2002294 0.91 PPARG (0.49) PPARGCYP3A4RORCMCL1PTGDR2
SCHEMBL2003082 0.91 PPARG (0.47) PPARGCYP3A4PTGDR2MAPTLMNA
SCHEMBL2003778 0.89 PPARG (0.48) PPARGCYP3A4RORC
SCHEMBL1998403 0.88 PTGDR2 (0.45) PPARGCYP3A4PTGDR2MAPTLMNA
SCHEMBL2001225 0.87 PPARG (0.49) PPARGCYP3A4MCL1PTGDR2MAPT
SCHEMBL2001848 0.85 RORC (0.42) PPARGCYP3A4RORCMAPTLMNA
SCHEMBL1998908 0.84 PPARG (0.49) PPARGCYP3A4MCL1PTGDR2MAPT
SCHEMBL1997017 0.84 PPARG (0.47) PPARGCYP3A4MCL1PTGDR2LMNA
SCHEMBL2000439 0.84 PPARG (0.51) PPARGCYP3A4RORCMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960408-B2 Quinolinyl and benzothiazolyl modulators AMGEN INC. (US) 2011-06-14 US disclosed
US-7601841-B2 Quinolinyl and benzothiazolyl modulators AMGEN INC. (US) 2009-10-13 US disclosed
US-20090221635-A1 QUINOLINYL AND BENZOTHIAZOLYL MODULATORS AMGEN INC. (US) 2009-09-03 US disclosed
EP-1296967-B1 BENZOTHIAZOLYL PPAR-GAMMA MODULATORS AMGEN INC (US) 2006-05-31 EP disclosed
US-20040176409-A1 Quinolinyl and benzothiazolyl modulators TULARIK INC 2004-09-09 US disclosed
US-20030171399-A1 Quinolinyl and benzothiazolyl modulators TULARIK INC. 2003-09-11 US disclosed
US-6583157-B2 Peroxisome proliferator-activated receptors antagonists; antiinflammatory agents and treating metabolic disorders TULARIK INC. 2003-06-24 US disclosed
EP-1296967-A1 QUINOLINYL AND BENZOTHIAZOLYL PPAR-GAMMA MODULATORS Tularik Inc. (US) 2003-04-02 EP disclosed
US-20020169185-A1 QUINOLINYL AND BENZOTHIAZOLYL MODULATORS AMGEN INC. 2002-11-14 US disclosed
WO-2002000633-A1 QUINOLINYL AND BENZOTHIAZOLYL PPAR-GAMMA MODULATORS TULARIK INC. (US) 2002-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040176409-A1 Quinolinyl and benzothiazolyl modulators PPARA, PPARG, PPARD PPARG 2/4885CYP3A4 675/4885RORC 42/4885
US-20030171399-A1 Quinolinyl and benzothiazolyl modulators PPARA, PPARG, PPARD PPARG 2/4885CYP3A4 675/4885RORC 42/4885
US-20020169185-A1 QUINOLINYL AND BENZOTHIAZOLYL MODULATORS PPARA, PPARG, PPARD PPARG 2/4885CYP3A4 675/4885RORC 42/4885
US-20090221635-A1 QUINOLINYL AND BENZOTHIAZOLYL MODULATORS PPARG, PPARA, PPARD PPARG 1/4885CYP3A4 772/4885RORC 35/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.